Domů › Uroteliální (přechodnobuněčný) karcinom › New York › New York City
Klinické studie Uroteliální (přechodnobuněčný) karcinom v New York City, NY
22 studií pro Uroteliální (přechodnobuněčný) karcinom hledá účastníky v lokalitách v New York City a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Probíhá náborFáze 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Probíhá náborFáze 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Probíhá náborObservační studie
- NYU Grossman School of Medicine, New York
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Probíhá náborFáze 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Probíhá náborFáze 1/2
- Icahn School of Medicine at Mount Sinai, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Probíhá náborFáze 1
- Columbia University Irving Medical Center, New York
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Probíhá náborFáze 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Probíhá náborFáze 1
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Probíhá náborFáze 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Probíhá náborFáze 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Probíhá náborFáze 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Probíhá náborFáze 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Probíhá náborFáze 1
- New York Cancer & Blood Specialists, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Probíhá náborFáze 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Probíhá náborFáze 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
- a dalších 2
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Probíhá náborFáze 3
- Research Site, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Probíhá náborFáze 2
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Probíhá nábor
- Integrated Medical Professionals, New York
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Probíhá náborFáze 1
- MSK, New York
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Probíhá náborObservační studie
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Probíhá náborFáze 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, New York
Studie Uroteliální (přechodnobuněčný) karcinom v jiných městech
- Nashville, TN23 studií
- Houston, TX19 studií
- Dallas, TX18 studií
- Edison, NJ18 studií
- Los Angeles, CA17 studií
- Queens, NY15 studií
- Chicago, IL14 studií
- Arlington, VA12 studií
- Boston, MA11 studií
- San Antonio, TX11 studií
- Austin, TX10 studií
- Orange, CA10 studií
Další studie v New York City
- Rakovina prsu136 studií
- Nemalobuněčný plicní karcinom121 studií
- Rakovina (všechny typy)109 studií
- Rakovina prostaty103 studií
- Metastatický karcinom93 studií
- Kolorektální karcinom78 studií
- Rakovina vaječníků69 studií
- Rakovina plic60 studií
- Mnohočetný myelom60 studií
- Rakovina slinivky břišní60 studií
- Rakovina endometria52 studií
- Akutní myeloidní leukemie51 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.